Development Milestone Event Development Milestone Payment. 1. [***] [***]
Development Milestone Event Development Milestone Payment. (i) First Regulatory Approval in the United States of an SMA Licensed Product $ [***] (ii) First occurrence of both (a) Regulatory Approval by the $ [***] CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Development Milestone Event Development Milestone Payment EMA or an MMC in the EU of an SMA Licensed Product and (b) Reimbursement Approval by an MMC in the EU of such SMA Licensed Product
Development Milestone Event Development Milestone Payment. (in Dollars)
Development Milestone Event Development Milestone Payment. 3. [*] $[*], in the form of cash or in the form of unregistered common stock of Licensee (valued using a 30-day VWAP of Licensee’s common stock traded on Nasdaq beginning on the date the milestone is publicly announced). For the avoidance of doubt, Licensor will have 10 days to elect whether to accept the payment in cash or stock. Notwithstanding the foregoing, if Licensee undergoes a Change in Control, any payment owed pursuant to this Development Milestone Event will be made in cash and not in stock.
Development Milestone Event Development Milestone Payment. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
Development Milestone Event Development Milestone Payment. [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] Total potential Development Milestone Payments $ 60,000,000
Development Milestone Event Development Milestone Payment. Achievement of [***] ([***]) sites (excluding sites in Greater China) activated (i.e., able to recruit patients for inclusion) in the MARIO Study $[***] On [***], patient dosing and/or data collection under the MARIO Study remains ongoing and the Independent Data Monitoring Committee has not recommended stopping it $[***] On [***], patient dosing and/or data collection under the MARIO Study remains ongoing [***] and the Independent Data Monitoring Committee has not recommended stopping it $[***] Decision by GSK to [***] in the MARIO Study [***] (the “[***] Milestone Event”) [***] Successful Completion of the MARIO Study $10,500,000 For clarity, each Development Milestone Payment shall be paid only one time, regardless of the number of studies conducted, the number of Products that achieve the corresponding Development Milestone Event or the number of Indications for which Products are Developed, and in no event will GSK be responsible for more than an aggregate of Seventy Five Million Five Hundred Thousand Dollars ($75,500,000) in Development Milestone Payments (not including the Development Milestone Payment for the Increased Enrollment Milestone Event). Following the Effective Date, Scynexis, as the Party responsible for achieving or determining such Development Milestone Event, shall notify GSK within [***] ([***]) following the achievement of a given Development Milestone Event and provide GSK with evidence demonstrating such achievement of such Development Milestone Event, and the corresponding Development Milestone Payment shall be due within [***] ([***]) after GSK’s receipt of a Valid Invoice in accordance with Section 6.7 for such Development Milestone Payment.
Development Milestone Event Development Milestone Payment. 1. Commencement of a Phase I Clinical Study for a Licensed Product or a Buck Licensed Product $[***]
Development Milestone Event Development Milestone Payment. 1.Receipt of NDA Approval from FDA Thirty Million Dollars ($30,000,000)* * [* * *]
Development Milestone Event Development Milestone Payment. Acceptance of an NDA for a Covered Product by the FDA [***] First Commercial Sale of a Covered Product in the United States [***] First Commercial Sale of a Covered Product in the EU [***]
